News from all angles
(MedPage Today) -- The oral GLP-1 receptor agonist orforglipron (Foundayo) improved sleep-disordered breathing in patients with moderate-to-severe obstructive sleep apnea and overweight or obesity, t…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network